The efficacy and safety of oral nadolol in supraventricular tachycardia were evaluated prospectively in 27 children (median age 5.5 years). Fifteen patients had an unsuccessful trial of digoxin therapy. Intravenous nadolol was given to seven patients during electrophysiologic study; five of these had an excellent response and two had a partial response (25% decrease in tachycardia rate). Six of these patients had a similar response to oral nadolol. Twelve patients received both propranolol and nadolol. Among six patients, intravenous propranolol was successful in four and unsuccessful in two; all six had a similar response to oral nadolol. With oral propranolol, tachycardia was well controlled in four patients and persistent in two; five of five patients had a similar response to oral nadolol.
Twenty-six patients were treated with oral nadolol; the arPropranolol, a beta-adrenoceptor blocking agent, and digoxin are used frequently as first-line drugs for supraventricular tachycardia in children (1, 2) . During the last decade, several new beta-adrenoceptor blocking agents have been approved by the U.S. Food and Drug Administration. Although these agents have many similar pharmacologic effects, they differ vastly in clinically important pharmacokinetic properties. One of these newer agents, nadolol (Corgard) is a nonselective beta-adrenoceptor blocking agent. It has been used in adults for the treatment of supraventricular and ventricular arrhythmias (3) (4) (5) (6) (7) (8) , hypertension and angina pectoris (9) . Unlike propranolol, it has a prolonged elimination half-life of 14 to 24 h, the longest of all beta-adrenoceptor blocking agents (10, 11) . Its once a day regimen with lack of significant side effects in adults (3) (4) (5) (6) (7) (8) makes it an attractive drug for use in children. However, its use in children has not been reported previously. The purpose of this study was to prospectively investigate 1) the efficacy and safety of intravenous and oral nadolol in children with recurrent symptomatic supraventricular rhythmia was well controlled in 23, 2 had recurrent tachycardia and 1 patient had tachycardia at a 25% slower rate. The effective dose of nadolol ranged between 0.5 and 2.5 mg/kg body weight once daily (median dose 1 mg/kg per day). During follow-up (3 to 36 months), compliance and tolerance were excellent; excluding 2 patients with reactive airway disease who developed wheezing, only 3 (12%) of 24 had side effects necessitating a change in drug therapy.
Once a day nadolol is a safe and effective agent in the management of supraventricular tachycardia in children. Its long-term efficacy can be predicted by the short-term response to intravenous nadolol or propranolol during programmed electrophysiologic study.
(J Am Coll CardioI1992; 19:630-5) tachycardia; 2) the ability of the response to intravenous or oral propranolol to predict the efficacy of oral nadolol in children with supraventricular tachycardia; 3) the effectiveness of a once a day dosing interval; and 4) the effective dosage range of nadolol.
Methods
Study patients. This prospective study included 27 children :;;18 years of age with symptomatic supraventricular tachycardia documented by a surface electrocardiogram (ECG) or ambulatory ECG recording, or both. Children with heart failure, sick sinus syndrome, atrial flutter or atrial fibrillation were excluded. All children were seen in the pediatric cardiac clinic by a cardiologist, either at St. Christopher's Hospital for Children, Philadelphia or James H. Quillen College of Medicine, Johnson City, Tennessee, between July 1985 and June 1991.
Patients selected for the intravenous nadolol protocol were required 1) to have supraventricular tachycardia that was refractory to digoxin therapy despite a documented therapeutic serum digoxin level; 2) to be undergoing clinically indicated electrophysiologic study; and 3) to have given prior written informed consent. Entry criteria for the oral nadolol protocol included any of the following: 1) complete or partial success (>25% decrease in tachycardia rate) of intravenous nadolol during electrophysiologic study; 2) unsuccessful treatment with digoxin despite a documented therapeutic digoxin level; 3) success of intravenous or oral propranolol, or both, with or without digoxin as assessed by history or ambulatory ECG recording; 4) questionable compliance with an oral propranolol regimen; and 5) the presence of a narrow QRS tachycardia on the ECG with or without a documented accessory bypass tract. The intravenous nadolol protocol was approved by the Institutional Review Board of St. Christopher's Hospital for Children and was used only at that center.
Study method. All children had a complete physical examination, a 12-lead surface ECG, a complete echocardiogram and an ambulatory (Holter) ECG recording.
Intravenous nadolol protocol. All antiarrhythmic drugs were discontinued 72 h before electrophysiologic study. The study was performed with the patient in a postabsorptive state under sedation with meperidine hydrochloride (2 mg/kg body weight to a maximum of 50 mg intramuscularly) and promethazine (0.5 mg/kg to a maximum of 12.5 mg intramuscularly). The electrophysiologic protocol included atrial extrastimuli on sinus or paced beats, or both, rapid atrial pacing for 30 s, ventricular extrastimuli on sinus or paced beats, or both, and burst ventricular pacing for eight beats. The extrastimuli were delivered at approximately twice diastolic threshold by means of a programmed digital stimulator. The extrastimuli were delivered at decreasing intervals, starting at approximately 80% of the sinus or paced cycle length. None of the patients received isoproterenol infusion in this study.
After the mechanism of supraventricular tachycardia was defined by the electrophysiologic protocol just described, a single dose of intravenous nadolol, 0.05 mg/kg to a maximum of 5 mg, was given over 2 min. Repeat electrophysiologic studies were performed at intervals of 15 and 30 min. The patient's blood pressure and ECG were continuously monitored. If tachycardia was inducible, a second identical dose of nadolol was given and the study was repeated at intervals of 15 and 30 min. If tachycardia was not induced, nadolol was considered successful and these patients entered the oral nadolol protocol.
Propranolol protocol. The intravenous dose of propranolol was 0.1 to 0.2 mg/kg to a maximum of 10 mg. The starting oral propranolol dose was 2 mg/kg per day, given in three or four doses, and was gradually increased until there was no clinical tachycardia, significant bradycardia (20% decrease in heart rate) or any significant side effects. Propranolol was considered successful if there was no inducible or clinical tachycardia during follow-up. Subsequently, these children were treated with nadolol according to the protocol.
Oral nadolol protocol. Children from the intravenous nadolol or the propranolol protocol and children who had not responded to digoxin or had not received any previous drug therapy were included in the oral nadolol protocol. The starting oral nadolol dose ranged from 0.5 to 1.5 mg/kg once daily. Each child was followed up with telemetry monitoring in the hospital or in outpatient examinations to detect adverse drug effects, clinical tachycardia or ECG changes. If tachycardia or adverse effects were not observed, the same dose was continued. If any episode of tachycardia recurred after the 4th day of therapy without side effects, the dose was increased gradually to a maximum of 2.5 mg/kg per day. If a child had recurrent tachycardia while receiving a maximal dose of nadolol or if side effects occurred, nadolol therapy was discontinued.
Follow-up. Efficacy and side effects were assessed by history, a complete physical examination and a 12-lead ECG at least every month for 2 months and every 6 months thereafter as needed. An ambulatory (Holter) ECG was performed routinely in all patients <10 years old. Additionally, an ambulatory ECG was performed in any child who had symptoms or bradycardia.
Results
Clinical data. Twenty-seven patients (19 male and 8 female) were treated with nadolol under the protocol. The age at the onset of supraventricular tachycardia ranged from 3 months to 15 years (median 6 years). All but one patient received oral nadolol therapy. Patients were classified into two groups: 1) Group I comprised 14 children who received intravenous or oral propranolol or nadolol, or both (Table 1) ; 2) Group II comprised 13 children who received only oral nadolol therapy (Table 2) . Tables 1 and 2 summarize the clinical characteristics of the patients in each group. Two patients (Table 1 , Patients 4 and 14) had congenital heart disease. Only one patient (Group I, Patient 1) had echocardiographic evidence of ventricular dysfunction.
The mechanisms ofsupraventricular tachycardia were as follows: an accessory bypass tract in 7 patients; atrioventricular (AV) node reentry in 4; automatic ectopic atrial tachycardia in 1patient; automatic ectopic junctional tachycardia in 2 patients; intraatrial reentry in 1 patient; sinus node reentry in 2 patients and narrow QRS reentrant supraventricular tachycardia in 10. Fifteen children had unsuccessful digoxin therapy.
Response to intravenous and oral nadolol (Table 1) . After intravenous nadolol, two patients (Group I, Patients 8 and 10) with AV node reentrant tachycardia had no inducible tachycardia; both were free of tachycardia on oral nadolol therapy during follow-up. One patient (Group I, Patient 3) with ectopic atrial tachycardia had conversion to sinus rhythm with intravenous nadolol therapy and good control of the arrhythmia with oral nadolol therapy. One patient (Group I, Patient 6) with AV reciprocating tachycardia had nonsustained inducible tachycardia « lO-s duration) after a second dose of intravenous nadolol, but oral nadolol provided excellent clinical control of the tachycardia. Another patient (Group I, Patient 7) showed similar responses, having nonsustained inducible tachycardia 30 min after a single dose of intravenous nadolol but no inducible tachycardia 45 min later; he was free of tachycardia with oral nadolol therapy during follow-up. Two other patients, one with AV node tachycardia and one with AV reciprocating tachycardia, had sustained inducible tachycardia after a single intra- venous nadolol dose, but the tachycardia rate decreased by 25%. This outcome was considered unsuccessful and one of these patients (Group I, Patient 5) had recurrent clinical tachycardia when oral nadolol was tried. Thus, in six of six patients with a successful result, the response to short-term intravenous administration of nadolol and long-term treatment with oral nadolol was concordant (Fig. 1, upper pane!) .
Comparison of response to propranolol and nadolol (Table  1, Fig. 1 ). Twelve patients received both drugs. Intravenous propranolol was successful in four of six patients (two patients with ectopic tachycardia and two with AV reciprocating tachycardia) but failed to control tachycardia in two patients; all six patients had a similar response to oral nadolol therapy. Only oral propranolol was tried in the remaining six patients; four had excellent clinical control and two had recurrent clinical tachycardia. Oral nadolol therapy was tried in five of these patients, who had similar responses. One patient (Group I, Patient 4) with AV reciprocating tachycardia had recurrent tachycardia despite adequate propranolol therapy and a slower but sustained inducible tachycardia (25% decrease in tachycardia rate) with intravenous nadolol; oral nadolol was not tried. Thus, the response to propranolol seemed to predict the results of long-term nadolol therapy in all patients except one child in whom oral nadolol was not tried.
Response to long-term oral nadolol therapy and its dosage. Of the 26 patients who received long-term oral nadolol therapy, 23 were free of tachycardia during a follow-up period of 3 to 36 months; 2 had recurrent tachycardia and 1 patient had recurrent tachycardia at a 25% slower rate. In 15 patients, digoxin, a first-line drug, had been unsuccessful. Of these 15 patients, 1 patient did not receive oral nadolol therapy because the response to intravenous nadolol was only partial (AV reciprocating tachycardia); in 3 other patients oral nadolol was unsuccessful (intraatrial reentry, AV reciprocating tachycardia and AV node reentry in 1 patient each). Of the four patients with recurrent tachycardia, one patient required ablative surgery, one is receiving ftecainide, one is receiving amiodarone and one was lost to follow-up.
The follow-up period in patients receiving oral nadolol ranged from 3 months to 3 years (median 1 year). The effective dose of nadolol in 23 patients who were free of tachycardia with this protocol ranged between 0.5 and 2.5 mg/kg per day, with a median effective dose of 1 mg/kg per day. Three patients received 2 mg/kg per day and one patient required 2.5 mg/kg per day of oral nadolol; all four patients tolerated this higher dose well during follow-up. Nine children remained free of tachycardia while receiving only 0.5 to 0.7 mg/kg per day ofnadolol, whereas three failed to respond despite doses of 1.5 to 2 mg/kg per day. Doses <0.5 mg/kg were not tried.
Safety of intravenous and oral nadolol. There was no significant change in blood pressure after infusion of nadolol. No patient developed second or third degree AV block after intravenous or oral nadolol. All patients had a 10% to 20% decrease in sinus rate, but none had symptomatic bradycardia with intravenous or oral nadolol. Of 26 patients on long-term oral nadolol therapy, 2 with inactive reactive airway disease had wheezing episodes requiring a change in drug therapy. One of these patients whose treatment was changed from nadolol to atenolol because of wheezing had persistent wheezing and required an oral bronchodilator.
Three other patients had symptoms necessitating changes in drug therapy as/allows: 1) a 3-month old boy had abdominal colic at night or nightmares (nadolol dose 1.5 mg/kg) that lessened after therapy was changed from nadolol to propranolol; 2) a 14-year old boy had sleep and personality changes (nadolol dose 0.7 mg/kg) and his treatment was changed to verapamil; 3) a 4-year old girl devel-
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Discussion
Oral nadolol therapy. Supraventricular tachycardia due to either AV node reentry or accessory bypass is the most common type of tachycardia in children. Empiric therapy with digoxin or propranolol, a first generation betaadrenoceptor blocking agent, or both, is effective in 64% of children with supraventricular tachycardia (12) . Like propranolol, nadolol is a nonselective competitive betaadrenoceptor blocking agent. However, nadolol has a much longer plasma half-life of 14 to 24 h (10,11). Nadolol also lacks intrinsic sympathomimetic activity and membranestabilizing properties. Once a day nadolol therapy has been shown to be effective in controlling various types of supraventricular tachycardia in adults (3) (4) (5) (6) (7) (8) .
In our study, 11 of 15 patients who did not respond to digoxin as the first-line drug had a good response to nadolol, whereas 12 children received propranolol or nadolol as a first-line drug with successful results. Thus, 23 of 26 children were free of tachycardia on long-term once a day nadolol therapy. Although atenolol, a selective betat-adrenoceptor blocking agent, has also been reported (13) to be successful in long-term prophylaxis of supraventricular tachycardia in children, nadolol has the advantage of having the longest plasma half-life among all available beta-adrenoceptor blockoped frequent headaches (nadolol dose 0.8 mg/kg) and her therapy was changed to oral digoxin. Three other patients had transient headaches and fatigue during the 1st week of therapy. Except for the 3-month old boy with abdominal colic, the children whose treatment drug was changed were receiving a low dose of oral nadolol «0.8 mg/kg). The four patients who received 2 to 2.5 mg/kg per day of oral nadolol had no side effects during follow-up. Adverse effects did not appear to be dose related. Response to IV Nadolol
Reaponse to oral Nadolol
Response to Propranolol
Resronse to Ora Nadolol ing agents. Furthermore, a high degree of concordance was observed between the response to intravenous nadolol during electrophysiologic study and the response to oral nadolol therapy in our study (six patients). Thus, a successful result with intravenous nadolol accurately predicts a clinically good response with long-term oral therapy in children. Similar results have been reported by other investigators (3, 4) in adults.
Comparison of propranolol and nadolol response in supraventricular tachycardia. As reported by Chang et al. (5) , the response to intravenous propranolol during electrophysiologic study correctly predicted the long-term response to oral nadolol therapy in all six of our patients. Because intravenous nadolol is not yet commercially available in the United States, the efficacy of oral nadolol can be predicted by the response to intravenous propranolol during electrophysiologic pharmacologic study. In our study, five patients who were treated first with oral propranolol and subsequently with oral nadolol had similar clinical responses in the control of tachycardia. This study shows that children who are being successfully treated with propranolol given three or four times a day can safely be given once a day oral nadolol therapy.
Gillette et al.
(1) reported a 25% failure rate with propranolol in the management of supraventricular tachycardia in children, the same rate as in our series (4 of 12 patients). Pickoff et al. (14) reported the need for high dose propranolol in the management of selected patients with supraventricular tachycardia. One reason for failure of propranolol in children is lack of compliance, which may be attributed to the need for three or four doses/day. Because propranolol is extensively metabolized by the liver, the dose requirement varies among children and large doses may be needed in some children for effective control of tachycardia (14) . Nadolol has several advantages over propranolol. Compliance with once a day nadolol therapy was excellent in our series, especially in school-aged children. It is not metabolized in humans and thus has no first-pass effect when taken orally. In comparison with 95% protein binding of propranolol, nadolol is only 25% protein bound. In contrast to all other beta-adrenoceptor blocking agents, nadolol has the unique property of renal vasodilation (15) (16) (17) . In experimental animals, nadolol causes significantly less direct myocardial depression (18) . Because of the long elimination half-life of nadolol, the possibility of abrupt withdrawal symptoms with this agent is less likely than with propranolol (19) . For these reasons, we recommend the use of nadolol over propranolol.
Safety. Beta-adrenoceptor blocking agents are well tolerated in adults and children. In general, these agents have a low incidence of proarrhythmia and a lack of organ toxicity, which are of concern with class I and class III antiarrhythmic agents. Because of its low lipid solubility, nadolol is thought to cross the blood-brain barrier less readily than propranolol, causing less central nervous system side effects. Despite the low lipid solubility of nadolol, three children had a transient history of headaches and fatigue; one patient had a sleep disorder and personality changes and another possibly had nightmares or abdominal colic. In patients with bronchospastic disease, a relatively selective betal-adrenoceptor blocking agent is commonly considered superior to a nonselective beta-blocking agent like nadolol (13, 20) . However, selectivity is restricted to low dosage (15, 20) and the therapeutic dosage of these agents may lie outside the selective range; furthermore, most tissues possess a mixed group of beta1-and betaz-adrenergic receptors, even though they may have predominantly one type of receptor (20) . Therefore, selective and nonselective betaadrenoceptor blocking agents must be used cautiously in children with bronchospastic disease. Overall, nadolol was well tolerated in our patients. In this study, the four patients who received a relatively high dose of 2 to 2.5 mg/kg per day of nadolol had no side effects. In children who had side effects, the dose of nadolol was 0.5 to 0.7 mg/kg, suggesting that these side effects were probably not dose related.
Conclusions. Nadolol, a nonselective beta-adrenoceptor blocking agent, seems to be safe and effective as a once a day drug in children with supraventricular tachycardia. The efficacy of oral nadolol can be predicted by the response to intravenous propranolol during electrophysiologic pharmacologic study. A safe starting oral dose of nadolol is 0.5 to 1 mg/kg per day. The drug is well tolerated with no significant short-or long-term adverse effects.
